Last reviewed · How we verify
D1553
At a glance
| Generic name | D1553 |
|---|---|
| Sponsor | InxMed (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors (PHASE1, PHASE2)
- A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (PHASE3)
- Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation (PHASE2)
- Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors (PHASE1, PHASE2)
- Study to Evaluate D-1553 in Subjects With Solid Tumors (PHASE1, PHASE2)
- A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Study to Evaluate D-1553 in Subjects With Lung Cancer (PHASE1, PHASE2)
- A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |